youtube_live
Q3 2026 earnings • released • EPS beat +११.३८% • Revenue beat +७.३३%
See resultschevron_right
AGIO:NASDAQ
Agios Pharmaceuticals Inc
US$ २९.४१
arrow_upward
+४.०३%(+१.१४) 1D
US$ २८.९७
arrow_downward
-१.५०% (-०.४४)bedtimeAfter hours
Closed: नोभेम्बर ६, १६:००:०१ GMT-५ · USD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for AGIO...
Open
US$ २८.९९
High
US$ २९.८०
Low
US$ २८.४६
Mkt. cap
१.७६ अरब
Avg. vol.
१२.८४ लाख
Volume
१२.८१ लाख
52-wk high
US$ ४५.९९
52-wk low
US$ २२.२४
EPS
-US$ ७.०१
Beta
०.६६
Shares outstanding
५.९७ करोड
No. of employees
५४०
Open
US$ २८.९९
High
US$ २९.८०
Low
US$ २८.४६
Mkt. cap
१.७६ अरब
Avg. vol.
१२.८४ लाख
Volume
१२.८१ लाख
52-wk high
US$ ४५.९९
52-wk low
US$ २२.२४
EPS
-US$ ७.०१
Beta
०.६६
Shares outstanding
५.९७ करोड
No. of employees
५४०
News stories
From web sources and news partners
TradingView
·
१ दिन पहिले
What Agios Pharmaceuticals (AGIO) Said on Its Q3 Earnings Call
Benzinga
·
१ दिन पहिले
Agios Pharmaceuticals Q3 2026 Earnings Call Transcript
GuruFocus
·
१ दिन पहिले
Agios Pharmaceuticals Reports Q3 2026 Revenue of $55.4 Million,
Profile
Agios Pharmaceuticals Inc. is a publicly trading American pharmaceutical company pioneering therapies for genetically defined diseases, with a near-term focus on developing therapies for hemolytic anemias. The company was founded in 2008 by Lewis Cantley, Tak Mak and Craig Thompson. Agios is a Delaware corporation headquartered in Cambridge, Massachusetts. The company tendered an initial public offering in July 2013. Wikipedia
About Agios Pharmaceuticals Inc